Several other equities analysts have also recently commented on the stock. Chardan Capital reiterated a buy rating and set a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. ValuEngine cut shares of Crispr Therapeutics from a hold rating to a sell rating in a research note on Friday, January 3rd. Needham & Company LLC reiterated a buy rating and set a $84.00 target price on shares of Crispr Therapeutics in a research note on Monday, December 23rd. Zacks Investment Research cut shares of Crispr Therapeutics from a hold rating to a sell rating in a research note on Monday, September 30th. Finally, Piper Jaffray Companies reiterated a buy rating and set a $104.00 target price on shares of Crispr Therapeutics in a research note on Monday, December 16th. Three analysts have rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $75.95.
NASDAQ:CRSP opened at $54.75 on Thursday. The stock has a market cap of $3.12 billion, a P/E ratio of -119.02 and a beta of 3.20. Crispr Therapeutics has a one year low of $29.34 and a one year high of $74.00. The company has a fifty day moving average price of $63.18 and a 200 day moving average price of $52.50. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, equities research analysts anticipate that Crispr Therapeutics will post 0.65 EPS for the current year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock worth $3,620,760 in the last three months. Insiders own 21.40% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. Nikko Asset Management Americas Inc. increased its holdings in Crispr Therapeutics by 48.4% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after buying an additional 906,006 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Orbimed Advisors LLC bought a new stake in shares of Crispr Therapeutics in the 3rd quarter worth about $21,167,000. Global Thematic Partners LLC grew its holdings in shares of Crispr Therapeutics by 1.7% in the 4th quarter. Global Thematic Partners LLC now owns 350,386 shares of the company’s stock worth $21,340,000 after purchasing an additional 5,764 shares during the last quarter. Finally, Morgan Stanley grew its holdings in shares of Crispr Therapeutics by 6.1% in the 2nd quarter. Morgan Stanley now owns 284,984 shares of the company’s stock worth $13,423,000 after purchasing an additional 16,361 shares during the last quarter. 49.83% of the stock is currently owned by hedge funds and other institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Closed-End Mutual Funds
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.